2 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Triple-Negative Breast Neoplasms: new trials by email Literature Review of Triple-Negative Breast Neoplasms trials Research Report on Triple-Negative Breast Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Trilaciclib, Gemcitabine, Carboplatin - Triple-Negative Breast Neoplasms, Breast Neoplasm | Phase 2 | Terminated | G1 Therapeutics, Inc. | 102 | 2017-02-02 | 2022-03-23 |
| A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors TAK-659, Nivolumab - Triple-Negative Breast Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Calithera Biosciences, Inc | 41 | 2016-08-12 | 2023-02-08 |
Triple Negative Breast Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Neoplasm Metastasis (1) · Squamous Cell Carcinoma of Head and Neck (1)
Breast Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Squamous Cell (1) · Head and Neck Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1)
Carboplatin (1) · Gemcitabine (1) · Nivolumab (1) · TAK-659 (1) · trilaciclib (1)
Calithera Biosciences, Inc (1) · G1 Therapeutics, Inc. (1)
United States (2) · Belgium (1) · Bulgaria (1) · Croatia (1) · Italy (1) · North Macedonia (1) · Serbia (1) · Slovakia (1) · Slovenia (1) · Spain (1) · United Kingdom (1)
2016 (2)